Market open
Capricor/$CAPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Capricor
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Ticker
$CAPR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
160
ISIN
US14070B3096
Website
Capricor Metrics
BasicAdvanced
$437M
-
-$1.42
0.86
-
Price and volume
Market cap
$437M
Beta
0.86
52-week high
$21.01
52-week low
$3.52
Average daily volume
2.4M
Financial strength
Total debt to equity
0.998
Management effectiveness
Valuation
Price to revenue (TTM)
21.356
Price to book
3
Price to tangible book (TTM)
3
Growth
Revenue change (TTM)
-35.92%
Earnings per share change (TTM)
65.27%
3-year revenue growth (CAGR)
339.82%
3-year earnings per share growth (CAGR)
13.88%
What the Analysts think about Capricor
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Capricor stock.
Capricor Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Capricor Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Capricor News
AllArticlesVideos
Securities Investigation: Levi & Korsinsky Investigates Capricor Therapeutics, Inc. (CAPR) on Behalf of Investors
Accesswire·2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Accesswire·2 days ago
Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Conference Call Transcript
Seeking Alpha·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Capricor stock?
Capricor (CAPR) has a market cap of $437M as of May 16, 2025.
What is the P/E ratio for Capricor stock?
The price to earnings (P/E) ratio for Capricor (CAPR) stock is 0 as of May 16, 2025.
Does Capricor stock pay dividends?
No, Capricor (CAPR) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Capricor dividend payment date?
Capricor (CAPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Capricor?
Capricor (CAPR) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.